Last reviewed · How we verify
NCT06227962: RbNeuroQoL
Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors
trial testing Neuropsychological assesment in Retinoblastoma in 240 participants. Enrolling by invitation.
30 October 2026
Quick facts
| Lead sponsor | Amsterdam University Medical Center |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 240 |
| Start date | 26 October 2023 |
| Primary completion | 30 October 2026 |
| Estimated completion | 31 March 2028 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Neuropsychological assesment
- Psychosocial functioning and quality of life (questionnaires)
- Parental psychosocial functioning (questionnaires)
Conditions studied
- Retinoblastoma — all drugs for Retinoblastoma →
- Neurocognitive Dysfunction — all drugs for Neurocognitive Dysfunction →
- Health-Related Behavior — all drugs for Health-Related Behavior →
Sponsor
Amsterdam University Medical Center
Who can join
Adults 6 Months to 35, any sex, with Retinoblastoma or Neurocognitive Dysfunction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A retrospective crosssectional observational study of the effects of oncological treatment and frequent general anesthesia on neuropsychological development, psychosocial functioning (in terms of anxiety, depression, peer relations, perceived cognitive functioning and potential trauma) and health related quality of life in children and young adults who were treated or screened for retinoblastoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06227962
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Retinoblastoma
Currently open trials in the same condition.
- NCT06725173 — Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra- · recruiting
- NCT06972602 — High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed · EARLY_PHASE1 · recruiting
- NCT06424301 — Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma · EARLY_PHASE1 · recruiting
- NCT06367530 — Trilateral Retinoblastoma: Incidence and Outcomes · recruiting
- NCT05650749 — GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06227962 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Amsterdam University Medical Center
- Last refreshed: 4 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06227962.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing